We are live on
!
Find out more
SCM
Superstring Capital Management Portfolio holdings
AUM
$140M
1-Year Est. Return
323.19%
This Fund
S&P 500
This Quarter
Est. Return
+49.53%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$140M
AUM Growth
–
Cap. Flow
+$107M
Cap. Flow
% of AUM
76.62%
Top 10 Holdings %
Top 10 Hldgs %
70.43%
Holding
30
New
30
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$11.9M |
| 2 |
ETNB
89bio
ETNB
|
+$9.39M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$9.08M |
| 4 |
IDEAYA Biosciences
IDYA
|
+$7.5M |
| 5 |
Immunovant
IMVT
|
+$7.49M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $17.7M | 12.66% |
+598,072
| New | +$11.9M |
|
2
Cytokinetics
CYTK
$10.9B
| $14.8M | 10.58% |
+177,603
| New | +$6.43M |
|
|
ETNB
3
DELISTED
89bio
ETNB
| $11.4M | 8.14% |
+1,021,477
| New | +$9.39M |
|
|
4
Ionis Pharmaceuticals
IONS
$8.99B
| $9.59M | 6.85% |
+189,618
| New | +$9.08M |
|
|
5
IDEAYA Biosciences
IDYA
$3.47B
| $8.94M | 6.38% |
+251,295
| New | +$7.5M |
|
6
Protagonist Therapeutics
PTGX
$9.06B
| $8.69M | 6.21% |
+379,143
| New | +$6.63M |
|
|
7
Immunovant
IMVT
$8.27B
| $8.58M | 6.12% |
+203,592
| New | +$7.49M |
|
8
BridgeBio Pharma
BBIO
$15.9B
| $8.33M | 5.95% |
+206,326
| New | +$6.2M |
|
|
DAWN
9
DELISTED
Day One Biopharmaceuticals
DAWN
| $5.54M | 3.96% |
+379,626
| New | +$4.6M |
|
|
MRNS
10
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $5.03M | 3.59% |
+462,444
| New | +$3.47M |
|
11
Neurocrine Biosciences
NBIX
$17.2B
| $3.87M | 2.76% |
+29,346
| New | +$3.38M |
|
12
UroGen Pharma
URGN
$1.96B
| $3.83M | 2.73% |
+255,430
| New | +$3.32M |
|
13
Savara
SVRA
$1.13B
| $3.83M | 2.73% |
+814,266
| New | +$3.12M |
|
14
Roivant Sciences
ROIV
$24.8B
| $3.66M | 2.61% |
+326,161
| New | +$3.18M |
|
15
Lantheus
LNTH
$7B
| $3.4M | 2.43% |
+54,896
| New | +$3.72M |
|
16
Fate Therapeutics
FATE
$324M
| $3.17M | 2.26% |
+847,823
| New | +$2M |
|
17
Keros Therapeutics
KROS
$211M
| $2.97M | 2.12% |
+74,649
| New | +$2.34M |
|
|
SLRN
18
DELISTED
ACELYRIN
SLRN
| $2.66M | 1.9% |
+356,924
| New | +$3.05M |
|
|
VRNA
19
DELISTED
Verona Pharma
VRNA
| $2.47M | 1.76% |
+124,040
| New | +$1.83M |
|
20
Nkarta
NKTX
$186M
| $2.29M | 1.64% |
+347,381
| New | +$900K |
|
21
Krystal Biotech
KRYS
$10.5B
| $2M | 1.42% |
+16,086
| New | +$1.78M |
|
22
Quanterix
QTRX
$182M
| $1.96M | 1.4% |
+71,760
| New | +$1.69M |
|
23
Axsome Therapeutics
AXSM
$11.8B
| $1.29M | 0.92% |
+16,179
| New | +$1.08M |
|
|
SY
24
So-Young International
SY
$169M
| $1M | 0.72% |
+796,059
| New | +$880K |
|
25
Immatics
IMTX
$1.31B
| $834K | 0.6% |
+79,213
| New | +$729K |
|
Similar funds
GIM
SLWM
NWA
WCM
JD6
CPC
CFG
RC
Superstring Capital Management's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Superstring Capital Management, which disclosed 30 positions worth $140M. Its ten largest holdings account for 70% of the portfolio.
Its largest position is Immunogen Inc: 598,072 shares worth $17.7M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets.
- Superstring Capital Management's largest Q4 2023 buy was Immunogen Inc: 598,072 shares worth $17.7M.
- Superstring Capital Management's ten largest holdings make up 70% of its $140M portfolio in Q4 2023.
- Superstring Capital Management disclosed 30 positions in Q4 2023, its first 13F filing on record.
Based on Superstring Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.